H. van der Leeuw

Publications (3)8.31 Total impact

• Source

  Available from: leidenuniv.nl

  Article: Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.

  U A Badrising, M Maat-Schieman, S G van Duinen, F Breedveld, P van Doorn, B van Engelen, F van den Hoogen, J Hoogendijk, C Höweler, A de Jager, F Jennekens, P Koehler, H van der Leeuw, M de Visser, J J Verschuuren, A R Wintzen
  [show abstract] [hide abstract]
  ABSTRACT: Epidemiologic data on inclusion body myositis (IBM) are scarce, and possibly biased, because they are derived from larger neuromuscular centers. The present nationwide collaborative cross-sectional study, which culminated on July 1, 1999, resulted in identification of 76 patients with IBM and the establishment of a prevalence of 4.9 patients with IBM per million inhabitants in the Netherlands. Several discrepancies suggest that this may be an underestimation. The most frequently identified pitfall in diagnosing IBM was an erroneous diagnosis of polymyositis or motor neuron disease.
  Neurology 12/2000; 55(9):1385-7. · 8.31 Impact Factor
• Article: Epidemiology of inclusion body myositis in the Netherlands: A nationwide study.

  U A Badrising, M. Maat-Schieman, S G van Duinen, F C Breedveld, P A van Doorn, B G M van Engelen, F H J van den Hoogen, J E Hoogendijk, C J Höweler, A.E.J. de Jager, F.G.I. Jennekens, P. Koehler, H. van der Leeuw, M de Visser, J J G M Verschuuren, A R Wintzen
• Article: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo

  U A Badrising, M. Maat-Schieman, M D Ferrari, A H Zwinderman, J.A.M. Wessels, F C Breedveld, P A van Doorn, B G M van Engelen, J E Hoogendijk, C J Höweler, A. de Jager, F.G.I. Jennekens, P. Koehler, H. van der Leeuw, M de Visser, A. Viddeleer, J J Verschuuren, A R Wintzen